CHMMF (Chimeric Therapeutics) Short Percentage of Float


CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHMMF vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Chimeric Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Short Percentage of Float falls into.


CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price